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Abstract (requirements: 150-250 words) 
Purpose. Perfluoroalkyl substances (PFAS) are used to make protective coatings on common household 
products. Prenatal exposures have been associated with developmental outcomes in offspring. Using 
data from the Avon Longitudinal Study of Parents and Children (ALSPAC), we investigated the 
association between prenatal concentrations of PFAS and bone health in girls at 17 years of age and 
whether body composition can explain any associations.  
Methods. We measured concentrations of perfluorooctane sulfonate (PFOS), perfluorooctanoate 
(PFOA), perfluorohexane sulfonate (PFHxS), and perfluorononanoate (PFNA) in maternal serum 
samples collected during pregnancy. We obtained bone health outcomes in the girls, such as bone 
mineral density, bone mineral content, bone area, and area adjusted bone mineral content from whole 
body dual-energy x-ray absorptiometry (DXA) scans. We used multivariable linear regression to explore 
associations between each PFAS and each bone health outcome with adjustment for important 
confounders such as girl’s age at clinic visit, maternal education, and gestational age at sample 
collection. We also controlled for girl’s height and lean mass to explore the role body composition had 
on observed associations. 
Results. Prenatal PFOS, PFOA, PFHxS and PFNA concentrations were associated with inverse effects 
on bone size and mass after adjusting for important confounders. Conversely, PFNA was positively 
associated with area-adjusted bone mineral content. However, most significant associations attenuated 
after additional controlling for height and lean mass.  
Conclusions. Prenatal concentrations of some PFAS may be associated with reduced bone mass and size 
in adolescent girls, although it is not clear whether these associations are driven by body size. 
Keywords: PFAS, ALSPAC, bone development, body composition, adolescent 
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Introduction 
Perfluoroalkyl substances (PFAS) are endocrine disrupting chemicals (EDCs) that can interrupt 
signaling pathways during fetal development through alteration of hormonal functions [1]. The chemical 
properties of PFAS can help create protective coatings on many household consumer products, such as 
food packaging, nonstick cookware, and textiles. PFAS are also used in the production of industrial 
products. While Europe and the U.S. have phased out production of some PFAS due to potential adverse 
health effects associated with exposure, they remain a public health concern because of their long half-
lives and persistent ability to accumulate in human tissues [2-5].  Common PFAS include 
perfluorooctane sulfonate (PFOS), perfluorooctanoate (PFOA), perfluorohexane sulfonate (PFHxS), and 
perfluorononanoic acid (PFNA). During critical periods of development, the developing fetus is 
particularly vulnerable to chemicals like EDCs that alter hormonal pathways [6]. PFAS are found in 
circulating blood and cord blood and are transferred to a fetus through the placenta during pregnancy. 
[6-8]. Toxicological studies indicate that certain PFAS accumulate in bone tissue in the fetus and could 
cause altered bone development [9].  
Several epidemiological studies have suggested a possible inverse relationship between various 
EDC exposures and bone health [10-13]. Specifically, two cross sectional studies using samples from 
the U.S. National Health and Nutrition Examination Survey (NHANES) have found lower bone mineral 
density with increased exposure to certain PFAS [13,12]. However, no studies to date have examined the 
relationship between in utero exposure to PFAS and bone health in offspring in adolescence.  
Our primary objective was to examine associations between maternal exposure to PFAS during 
pregnancy and their daughters’ bone health at 17 years of age using data from mothers and daughters in 
the Avon Longitudinal Study of Parents and Children (ALSPAC). Given the close dependency of bone 
mass acquisition on growth and body composition [14], we were also keen to establish whether any 
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observed associations between prenatal PFAS and measures of bone health could be explained by 
height, fat or lean mass. 
Methods 
Study Design and Population 
ALSPAC is a birth cohort that recruited pregnant women with expected delivery dates between 
April 1991 and December 1992. The study enrolled 14,541 pregnant women and their children at birth 
from three health districts of the former Avon region in South West England. Previous papers have 
described recruitment methods [15,16]. Enrolled mothers and children provided biological samples, 
completed questionnaires and participated in clinical assessments. The study website contains additional 
details for all available data through a fully searchable data dictionary 
(http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/). 
The current analysis uses data from an ancillary nested case-control study originally designed to 
study the association between prenatal EDC exposure and timing of menarche [17]. We selected data for 
our study from the original sample where we defined case subjects as girls who had early menarche 
(before 11.5 years of age) and control subjects were a random sample of remaining girls. Among the 448 
mother-daughter dyads from the original nested case-control study, 257 have measured maternal 
gestational blood concentrations for all studied PFAS and a complete whole body dual energy X-ray 
absorptiometry (DXA) scan done during the daughters’17 year-old clinic visit. We obtained approval for 
the study from the ALSPAC Ethics and Law Committee, the Local Research Ethics Committees, and the 
Centers for Disease Control and Prevention (CDC) Institutional Review Board. Mothers provided 
written informed consent for participation in the study. 
[18]Laboratory Analysis 
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Researchers at ALSPAC transferred blood samples under controlled conditions to the National 
Center for Environmental Health laboratories of the CDC for analysis. The lab measured serum levels of 
PFOS, PFOA, PFHxS, and PFNA in maternal blood collected at a median gestational age of 15 weeks. 
Laboratory methods have been described previously [18] . Limits of detection for the assays were 0.2 
ng/mL for PFOS, 0.1 ng/mL for PFOA, 0.1 ng/mL for PFHxS, and 0.08 ng/mL for PFNA. Quality 
control measures were implemented using standards, reagent blanks, and study samples. Precision of 
measurements for the analytes, as relative standard deviation, ranged from 8 to 13%. 
Data collection 
 All of the daughters included in our study (n=257) completed a DXA scan at 17 years of age. A 
Lunar prodigy narrow fan beam densitometer (GE Medical Systems Lunar, Madison, WI, USA) was 
used to perform a whole body DXA scan, from which total body less head bone mineral content (BMC), 
bone mineral density (BMD), bone area (BA), fat mass, and lean mass were obtained, as was area-
adjusted BMC (ABMC). A DXA scan of the left hip, from which total and femoral neck BMD were 
obtained, was performed at the same time. Height was measured using a Harpenden Stadiometer 
(Holtain, Crymych, Pembs, UK). Some daughters (n=230) also completed tibial peripheral quantitative 
computerized topography (pQCT) using the Statex XCT2000L (Stratec, Pforzheim, Germany) at 17 
years of age. pQCT measures the parameters of the tibia in detail and provides a more comprehensive 
assessment of bone than DXA scans during developmental ages [19].  Cortical BMC (BMCc), cortical 
BMD (BMDc), and cortical BA (BAc) were measured from the pQCT scan with XCT custom software 
version 6.00B. A circular ring model was used to derive periosteal circumference (PC) and cortical 
thickness (CT). A threshold above 650 mg/cm3 was used to define cortical bone [20]. 
Plasma was separated from sample and frozen at -80 degrees Celsius within 4 hours from 
collection. Plasma concentrations of β-C-telopeptides of type I collagen (CTX), a marker for bone 
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turnover, were measured using electrochemiluminescence immunoassays (Roche Diagnostics, Lewes, 
UK) in fasting samples collected around 15 years of age (n=120).  
 ALSPAC researchers collected covariate data on mothers and daughters through medical records 
and questionnaires. We characterized low birth weight as less than 2,500 g at delivery. Researchers 
collected information on maternal pre-pregnancy body mass index (BMI), education, ethnicity, age at 
delivery, and smoking status during pregnancy. We collected data on whether the child was ever 
breastfed by questionnaire at 15 months of age. Age at menarche was determined from questionnaires 
obtained throughout childhood and early menarche was defined as younger than 11.5 years of age [21].  
Statistical Analysis 
 We measured associations between maternal PFAS concentrations and bone health outcomes 
using weighted linear regression models, with weights inversely proportional to selection probabilities. 
To account for the original nested case-control study design, we weighted the sample to adjust for 
under-representation of the true number of girls without early menarche (weight for cases was 1 and for 
controls was 15.1). All exposure and outcome variables were continuous. Potential confounding 
variables were selected a priori for consideration in model selection and backwards elimination was 
used to determine which confounders were important contributors (Model 1) [22]. We evaluated 
associations by examining beta coefficients of the exposure, representing the estimated change in bone 
measure with a one unit (ng/mL) higher PFAS concentration, and their 95% confidence intervals. A 
negative beta coefficient represents a lower bone measure associated with a one unit (ng/mL) higher 
PFAS concentration. We then first evaluated the associations between PFAS and bone measures in 
models that adjusted for the following confounders: maternal education, gestational age at maternal 
serum sample collection, and daughter’s age at clinic visit. To explore the possible role of growth and 
body composition in the observed associations, we then examined other models adjusted for height and 
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body composition, guided by results of univariate regression analysis. We used complete cases for all 
analyses. SAS version 9.2 (SAS Institute Inc., Cary, NC) was used to conduct all analyses. 
Results 
 Table 1 describes demographic characteristics of our sample of 257 mother daughter dyads. 
Overall, mean (SD) maternal PFOS, PFOA, PFHxS, and PFNA concentrations were 21.92 (10.72) 
ng/mL, 4.08 (1.83) ng/mL, 2.59 (5.36) ng/mL, and 0.56 (0.22) ng/mL, respectively. Table 2 presents 
means of the bone health outcomes examined in the study.  
  After adjusting for confounders (age at clinic visit, maternal education, and gestational age at 
sample collection), several of the PFAS studied showed weak associations with parameters obtained 
from whole body DXA scans. ABMC was positively associated with each of the PFAS. A one ng/mL 
higher PFOS was associated with a -0.0008 g/cm2 (95% CI: -0.002, 0.000) lower BMD, -5.94 g (95% 
CI: -10.96, -0.92) lower BMC, -4.07 cm2 (95% CI: -7.38, -0.76) lower BA and 0.76g (95% CI: -0.78, 
2.31) higher ABMC (Table 3). Similarly, a one ng/mL higher PFNA was associated with a -0.0152 
g/cm2 (95% CI: -0.055, 0.025) lower BMD, -254.44 g (95% CI: -457.08, -51.80) lower BMC,-207.03 
cm2 (95% CI: -339.82, -74.25) lower BA, but an 86.33 g (95% CI: 24.61, 148.05) higher ABMC. We 
also found weak evidence of inverse association between PFOA and bone area, but little or no 
association with PFHxS concentration.  
To explore any effects of body size on these associations, we examined the association between 
maternal PFAS serum concentrations and fat mass, lean mass, and height of the daughter individually 
using linear regression to help design regression models looking at effects on bone health. We found 
moderate associations between certain PFAS and total lean mass and height, however weaker or no 
associations with fat mass (Supplemental Table 1). Based on these preliminary results, we adjusted for 
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height and lean mass individually and together with important confounders to examine whether 
associations seen between PFAS and bone health were direct effects independent of body composition.  
Following adjustment for height alone, associations with PFOS, PFOA and PFNA and bone 
parameters were all attenuated. Adjustment for lean mass alone, or height plus lean mass, led to similar 
attenuation of associations between PFOS and BMC and BA to that seen for height adjustment. 
Associations between PFOA and BA, and between PFNA and BMC, BA and ABMC, were unaffected 
by lean mass adjustment. 
Associations with additional bone measures at 15 and 17 years of age available for a subset of 
the population can be found in supplemental material. Mean and standard deviation of plasma CTX 
levels, pQCT, and hip DXA measures can be found in Supplemental Table 2. After adjusting for 
important confounders, weak or no associations were found between maternal PFAS concentrations and 
CTX levels at 15 years of age (Supplemental Table 3), tibial pQCT outcomes at 17 years of age 
(Supplemental Table 4), or total hip or femoral neck BMD measured with hip DXA at 17 years of age 
(Supplemental Table 5). 
Discussion 
 In our study of the potential association between prenatal PFAS concentrations and several 
markers of bone health in girls during adolescence, we found moderate inverse associations with bone 
size and mass in confounder-adjusted analyses. These associations attenuated after additional adjustment 
for body composition variables, height and lean mass. Conversely, we found PFNA to be directly related 
to ABMC.  
 Measures of body size including fat mass, lean mass, and height, have been found to be 
associated with bone mineral density [23,14]. Our results suggest that the effect of prenatal PFAS 
exposure on body size may influence the effect of PFAS exposure on bone health measures, given the 
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attenuation of the associations we observed by height adjustment. However, the precise mechanisms 
appeared to differ since associations with PFOS were attenuated to a similar extent by height and lean 
mass adjustment, whereas those for PFOA and PFNA were only attenuated by height adjustment.  
The mechanism through which body size influences the association between maternal PFAS 
concentrations on bone health remains unclear. In a previous ALSPAC study of 447 mother daughter 
dyads, maternal PFAS concentrations were associated with fetal and postnatal growth. While a negative 
association was seen between PFAS exposure and birthweight, a  positive association was seen between 
PFOS and weight at 20 months [17]. Addition of birthweight to the models presented in this analysis did 
not change the results (data not shown). An ancillary study (n=359) found no association between 
prenatal PFAS exposure and percent body fatness in ALSPAC girls at 9 years of age overall [24].  
 However, previous studies have reported positive associations between PFAS and body size, 
such as body fatness, lean mass, and height, which is highly related to bone measures. A Danish cohort 
study with similar PFAS exposure reported an association between maternal serum PFOA 
concentrations during pregnancy and adiposity in female offspring at 20 years of age (n=345) [25]. The 
direct association seen in other cohort studies between body size and BMD would suggest that maternal 
PFAS concentrations would also be positively association with BMD. In the present study, after 
controlling for body size, such as height and lean mass, most of the associations between maternal PFAS 
exposure and BMD, BMC, and BA remain negative.  However, positive associations were seen between 
maternal PFAS concentrations and AMBC, a bone measure less dependent on body size, possibly 
reflecting a reciprocal relationship between bone size and volumetric bone mineral density as previously 
reported in this cohort on pQCT scan [26] 
 There are many risk factors for fractures and discussing early life factors in relation to fracture 
risk later in life is particularly important when discussing implications of our findings on future skeletal 
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health. Bone size is an important determinant of fracture risk in biomechanical terms, however, it is 
unclear how total body measures used in our study relate to fracture risk in childhood and later in life 
[27]. A previous ALSPAC study found total body BMD to be associated with fracture risk in childhood; 
however, the actual parameters used in the previous study, such as BMD adjusted for body size, were 
not significantly associated with prenatal PFAS concentrations in the current study [28]. Additionally, 
while hip BMD is known to predict subsequent fracture risk, we did not observe a significant association 
with prenatal PFAS exposure. Toxicological studies have reported that maternal exposure can result in 
PFAS accumulation in bone tissues and causes decreases in bone mineral density, particularly with 
PFOA [9]. 
 To our knowledge, no previous epidemiologic studies have examined the association between in 
utero PFAS exposure and bone health later in life. However, using cross sectional data from NHANES, 
two studies reported inverse associations between PFAS exposure and bone health in women, results of 
which are consistent with those reported here. The first study used data on 2,339 adults from the 2005–
2006 and 2007–2008 cycles of NHANES to examine the association between serum concentrations of 
PFOA and PFOS and total lumbar spine and total hip BMD in adults. This study found inverse 
associations between serum PFOS concentrations and total lumbar spine BMD in premenopausal 
women [12]. A second study using samples from the 2009–2010 NHANES population found similar 
results. This study found among adult women overall, higher serum PFOS and PFHxS concentrations 
were associated with lower BMD and higher prevalence of osteoporosis [13]. Although these studies 
suggest a relationship between PFAS exposure and bone health in adults through the possible disruption 
of hormonal functioning, they do not examine the potential prenatal effects of PFAS in utero exposure 
on subsequent bone development through adolescence.  
 There are potential limitations to the current analyses. We weighted linear regression models to 
account for study design; however, bias may be introduced by analyzing data from a sample population 
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originally selected for a nested case-control study for another outcome. When comparing the sample 
used for the current analysis (n=257) to the original sample 448 mother daughter dyads, the current 
sample included more mothers in the higher education categories. Blood samples for maternal PFAS 
concentrations were only collected once during pregnancy and were assumed to be both indicators of 
exposure throughout pregnancy and a proxy for fetal exposure. We controlled for gestational age at 
sample collection to account for variability in the timing of sample collection across pregnancies. 
 In conclusion, prenatal PFAS exposure may be associated with bone mass and size in adolescent 
girls; however, it is unclear whether these associations are mostly explained by the effects of PFAS on 
body size. Additional research about the implications of these results for skeletal health, including 
fracture risk, can help further explain the relationship between prenatal exposures to environmental 
exposures, such as PFAS, and bone health. 
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Table 1. Characteristics of study population (n=257) for mothers and daughters enrolled in ALSPAC with maternal serum concentrations and DXA measures at 17 years of 
age. 
  Frequency   [n (%)] 
PFOS (ng/mL)                                
[Median (IQRa)] 
PFOA (ng/mL)                       
[Median (IQRa) 
PFHxS (ng/mL)                      
[Median (IQRa) 
PFNA (ng/mL)                     
[Median (IQRa))] 
Overall 257 (100) 20.2 (15.6, 25.5) 3.8 (2.9, 4.9) 1.7 (1.3, 2.3) 0.6 (0.4, 0.7) 
Maternal Prepregnancy BMI           
    Underweight (<18.5 kg/m2) 13 (5.1) 17.0 (14.0, 22.6) 3.4 (2.8, 4.7) 1.5 (1.3, 2.0) 0.5 (0.3, 0.6) 
    Normal (18.5-24.9 kg/m2) 169 (65.8) 20.5 (15.5, 25.5) 3.9 (2.9, 5.1) 1.8 (1.2, 2.4) 0.6 (0.4, 0.7) 
    Overweight (25.0-29.9 kg/m2) 40 (15.6) 21.2 (18.6, 25.9) 3.4 (3.3, 5.1) 1.9 (1.6, 3.1) 0.6 (0.5, 0.7) 
    Obese (≥30.0 kg/m2) 15 (5.8) 17.4 (13.1, 21.2) 3.0 (2.6, 4.3) 1.3 (1.1, 1.7) 0.5 (0.3, 0.7) 
Maternal Educationb       
    Less than O level 31 (12.1) 19.3 (17.0, 22.5) 3.8 (2.9, 4.9) 1.7 (1.4, 2.4) 0.6 (0.4, 0.7) 
    O level 90 (35.0) 19.9 (14.9, 25.6) 3.8 (2.9, 4.9) 1.6 (1.2, 2.3) 0.6 (0.4, 0.7) 
    Greater than O level 128 (49.8) 20.8 (15.8, 25.4) 4.0 (2.9, 5.0) 1.8 (1.3, 2.3) 0.5 (0.4, 0.7) 
Maternal Race       
    White 248 (96.5) 20.4 (15.7, 25.5) 3.9 (2.9, 5.0) 1.7 (1.3, 2.3) 0.6 (0.4, 0.7) 
    Nonwhite 4 (1.6) 18.4 (14.7, 22.4) 2.9 (2.4, 3.2) 1.6 (1.2, 1.7) 0.7 (0.5, 0.7) 
Maternal Age at Delivery (years)       
    <25  45 (17.5) 21.7 (15.6, 25.5) 4.4 (3.3, 5.1) 1.7 (1.3, 2.4) 0.6 (0.4, 0.7) 
    25–29 92 (35.8) 20.1 (15.9, 25.1) 3.8 (3.0, 4.9) 1.6 (1.2, 2.1) 0.6 (0.4, 0.7) 
    ≥29  119 (46.3) 20.1 (15.5, 25.6) 3.7 (2.7, 4.8) 1.9 (1.3, 2.5) 0.5 (0.4, 0.7) 
Maternal Smoking Status during first 3 months of pregnancy       
    Yes 56 (21.8) 19.0 (13.6, 23.5) 3.4 (2.8, 4.7) 1.7 (1.3, 2.5) 0.5 (0.3, 0.7) 
    No 197 (76.7) 21.1 (16.4, 25.5) 3.9 (2.9, 5.0) 1.7 (1.3, 2.2) 0.6 (0.4, 0.7) 
Low Birth Weight (<2,500g at delivery)       
    Yes 11 (4.3) 28.5 (18.9, 38.2) 4.2 (3.3, 5.6) 1.6 (1.4, 2.7) 0.7 (0.6, 0.7) 
    No 246 (95.7) 20.2 (15.5, 25.1) 3.8 (2.9, 4.9) 1.7( 1.3, 2.3) 0.6 (0.4, 0.7) 
Preterm Delivery (<37 weeks gestation)       
   Yes 8 (3.1) 27.5 (23.1, 40.6) 4.8 (4.0, 6.1) 1.8 (1.4, 2.5) 0.7 (0.6, 0.8) 
   No 248 (96.5) 20.2 (15.6, 25.2) 3.8 (2.9, 4.9)_ 1.7 (1.3, 2.3) 0.6 (0.4, 0.7) 
Ever Breastfed       
  
    Yes 209 (81.3) 20.4 (15.6, 25.5) 3.8 (2.9, 4.9) 1.7 (1.3, 2.4) 0.6 (0.4, 0.7) 
    No 35 (13.6) 18.3 (16.7, 23.4) 3.8 (3.1, 4.9) 1.7 (1.4, 2.3) 0.5 (0.4, 0.6) 
Early Menarche       
   Yes 131 (51.0) 19.7 (16.2, 25.2) 3.9 (2.9, 5.3) 1.8 (1.3, 2.3) 0.6 (0.4, 0.7) 
   No 126 (49.0) 21.2 (15.2, 25.5) 3.8 (2.7, 4.7) 1.7 (1.2, 2.3) 0.5 (0.4, 0.7) 
a Interquartile range 
b O-level= ordinary level; <O-level=none, Certificate of Secondary Education, or Vocational education; >O-level= Advanced level 
 
Table 2. Mean and standard deviation of total body less head bone variables measured by dual energy X-ray absorptiometry (DXA) scans at 17 years of age 
 
N Mean SD 
Bone Mineral Density (g/cm2)  257 1.05 0.07 
Bone Mineral Content (g)  257 2070.02 363.31 
Bone Area (cm2)  257 1964.63 236.79 
Area Adjusted Bone Mineral Content (g) 257 2253.85 113.74 
 
 
 
 
 
 
 
 
  
Table 3. Regression coefficients (β) for the association between maternal PFAS concentrations (ng/mL) and total body less head bone variables measured by dual energy X-
ray absorptiometry (DXA) scans at 17 years of age (n=248) 
  Bone Mineral Density (g/cm2) Bone Mineral Content (g) Bone Area (cm2) 
Area Adjusted Bone Mineral 
Content (g) 
  β 95% CI β 95% CI β 95% CI β 95% CI 
PFOS                 
Model 1a -0.0008 (-0.002, 0.000) -5.94 (-10.96, -0.92) -4.07 (-7.38, -0.76) 0.76 (-0.78, 2.31) 
Model 2b -0.0003 (-0.001, 0.001) -2.08 (-6.20, 2.04) -1.23 (-3.75, 1.30) -0.06 (-1.49, 1.37) 
Model 3c 0.0000 (-0.001, 0.001) -2.02 (-5.98, 1.94) -1.63 (-4.33, 1.07) 0.66 (-0.91, 2.23) 
Model 4d 0.0000 (-0.001, 0.001) -0.98 (-4.69, 2.72) -0.69 (-3.05, 1.68) 0.14 (-1.26, 1.54) 
PFOA                 
Model 1a -0.0020 (-0.007, 0.003) -21.95 (-48.52, 4.63) -16.98 (-34.47, 0.52) 6.00 (-2.13, 14.12) 
Model 2b 0.0012 (-0.004, 0.006) 3.50 (-18.36, 25.35) 1.70 (-11.70, 15.10) 0.70 (-6.90, 8.30) 
Model 3c -0.0015 (-0.006, 0.003) -19.55 (-40.03, 0.93) -15.48 (-29.40, -1.55) 5.92 (-2.21, 14.05) 
Model 4d -0.0011 (-0.005, 0.003) -5.94 (-25.68, 13.79) -2.99 (-15.60, 9.62) -1.02 (-8.48, 6.44) 
PFHxS                 
Model 1a -0.0002 (-0.002, 0.002) -2.24 (-11.12, 6.63) -1.61 (-7.46, 4.25) 0.40 (-2.31, 3.11) 
Model 2b 0.0001 (-0.002, 0.002) -0.08 (-7.21, 7.05) -0.01 (-4.38, 4.35) -0.06 (-2.53, 2.42) 
Model 3c 0.0006 (-0.001, 0.002) 2.48 (-4.40, 9.37) 1.35 (-3.34, 6.05) 0.26 (-2.47, 2.99) 
Model 4d 0.0006 (-0.001, 0.002) 2.26 (-4.16, 8.67) 1.15 (-2.95, 5.24) 0.37 (-2.05, 2.79) 
PFNA                 
Model 1a -0.0152 (-0.055, 0.025) -254.44 (-457.08, -51.80) -207.03 (-339.82, -74.25) 86.33 (24.61, 148.05) 
Model 2b 0.0102 (-0.028, 0.049) -52.55 (-220.64, 115.54) -59.49 (-162.33, 43.34) 45.37 (-12.85, 103.58) 
Model 3c 0.0009 (-0.032, 0.034) -164.58 (-322.21, -6.96) -151.14 (-257.81, -44.47) 84.19 (22.18, 146.20) 
Model 4d 0.0044 (-0.029, 0.038) -77.08 (-227.76, 73.60) -71.73 (-167.72, 24.27) 40.98 (-15.82, 97.78) 
a Adjusted for age at clinic visit, maternal education, and gestational age at sample collection 
b Adjusted for age at clinic visit, maternal education, gestational age at sample collection, and height 
c Adjusted for age at clinic visit, maternal education, gestational age at sample collection, and lean mass 
d Adjusted for age at clinic visit, maternal education, gestational age at sample collection, height, and lean mass 
 
 
  
Supplemental Tables 
Supplemental Table 1. Regression coefficients for the association between maternal serum PFAS concentrations (ng/mL) during pregnancy and daughter’s 
physiological characteristics at 17 years of age (n=221) 
  Total Fat Mass (g) Total Lean Mass (g) Height (cm) 
  β 95% CI β 95% CI β 95% CI 
PFOS a -56.00 (-192.76, 80.75) -75.61 (-131.12,  -20.10) -0.11 (-0.19,  -0.02) 
PFOA a 105.88 (-621.59, 833.34) -23.95 (-323.77, 275.87) -0.60 (-1.06,  -0.14) 
PFHxS a -61.45 (-297.22, 174.31) -99.91 (-196.18,  -3.63) -0.09 (-0.24, 0.06) 
PFNAa -4229.72 (-10050.00, 1591.01) -1119.89 (-3535.31, 1285.53) -5.20 (-8.88,  -1.52) 
a Adjusted for maternal pre-pregnancy BMI, maternal education, maternal age at delivery, gestational age at sample collection, and ever breastfed status at 15 
months 
Supplemental Table 2. Mean and standard deviation of plasma concentrations of β-C-telopeptides of type I collagen (CTX) at 15 years of age and a tibial 
peripheral quantitative computerized topography measures at 17 years of age 
 N Mean SD 
CTX (ng/mL) 120 0.66 0.25 
Cortical Bone Area (cm2) 230 271.02 36.26 
Cortical Bone Mineral Content(mg) 230 307.79 41.43 
Cortical Bone Mineral Density (mg.cm-2) 230 1135.72 24.95 
Periosteal Circumference (mm) 230 68.45 4.49 
Cortical Thickness (mm) 230 5.20 0.58 
Endosteal Circumference (mm) 230 35.76 4.55 
Total Hip Bone Mineral Density (g/cm2) 244 1.06 0.13 
Total Femoral Neck Bone Mineral Density (g/cm2) 250 1.05 0.13 
 
 
  
Supplemental Table 3. Regression coefficients (β) for the association between maternal PFAS concentration (ng/mL) and β-C-telopeptides of type I collagen in 
daughters at 15 years of age (n=116) 
  
β-C-telopeptides of type I 
collagen  (ng/mL) 
  β 95% CI 
PFOS     
Model 1a -0.003 (-0.008, 0.002) 
PFOA     
Model 1a -0.013 (-0.039, 0.012) 
PFHxS     
Model 1a -0.004 (-0.011, 0.003) 
PFNA     
Model 1a -0.123 (-0.397, 0.149) 
 
 
 
 
 
 
 
 
 
 
 
  
Supplemental Table 4. Regression coefficients (β) for the association between maternal PFAS concentration (ng/mL) and tibial peripheral quantitative 
computerized topography measures in daughters at 17 years of age (n=222) 
  
Cortical Bone Area 
(cm^2)  
Cortical Bone Mineral 
Content(mg)  
Cortical Bone Mineral 
Density (mg.cm^-2) 
Periosteal 
Circumference (mm) 
Cortical thickness (mm) 
Endosteal 
Circumference (mm) 
  β 95% CI β 95% CI β 95% CI β 95% CI β 95% CI β 95% CI 
PFOS                         
Model 1a -0.11 (-0.62, 0.41) -0.19 (-0.78, 0.41) -0.24 (-0.53, 0.06) -0.01 (-0.08, 0.06) 0.001 (-0.01, 0.01) 0.004 (-0.07, 0.07) 
PFOA                         
Model 1a 0.14 (-2.57, 2.85) -0.12 (-3.23, 2.99) -1.03 (-2.59, 0.53) -0.01 (-0.36, 0.35) 0.004 (-0.04, 0.05) -0.03 (-0.40, 0.33) 
PFHxS                         
Model 1a -0.06 (-0.95, 0.81) -0.05 (-1.06, 0.95) 0.07 (-0.44, 0.58) -0.01 (-0.13, 0.10) 0.000 (-0.01, 0.01) -0.02 (-0.13, 0.10) 
PFNA                         
Model 1a -6.51 (-27.28, 14.26) -9.99 (-33.78, 13.80) -10.19 (-22.13, 1.75) -1.87 (-4.56, 0.83) 0.048 (-0.28, 0.38) -2.16 (-4.95, 0.62) 
a Adjusted for age at clinic visit, maternal education, and gestational age at sample collection 
Supplemental Table 5. Regression coefficients (β) for the association between maternal PFAS concentration (ng/mL) and measures from dual energy X-ray 
absorptiometry (DXA) of the hip in daughters at 17 years of age (n=222) 
  
Total hip bone mineral 
density (g/cm2) (n=236) 
Total femoral neck bone 
mineral density (g/cm2) 
(n=242) 
  β 95% CI β 95% CI 
PFOS         
Model 1a -0.001 (-0.003, 0.001) -0.001 (-0.003, 0.001) 
PFOA         
Model 1a -0.003 (-0.012, 0.006) -0.003 (-0.013, 0.006) 
PFHxS         
Model 1a 0.000 (-0.003, 0.003) -0.001 (-0.004, 0.002) 
PFNA         
Model 1a 0.012 (-0.059, 0.083) -0.023 (-0.095, 0.050) 
 
a Adjusted for age at clinic visit, maternal education, and gestational age at sample collection 
